{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04634435",
            "orgStudyIdInfo": {
                "id": "BHV1100-101 (formerly KP001)"
            },
            "organization": {
                "fullName": "Biohaven Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients",
            "officialTitle": "A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 (Formerly KP1237) and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission",
            "therapeuticArea": [
                "Other"
            ],
            "study": "autologous-memory-like-nk-cell-therapy-with-bhv-formerly-low-dose-il-in-multiple-myeloma-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-10-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-10-21",
            "studyFirstSubmitQcDate": "2020-11-12",
            "studyFirstPostDateStruct": {
                "date": "2020-11-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-28",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Biohaven Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Dana-Farber Cancer Institute",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT)."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Myeloma"
            ],
            "keywords": [
                "Cell Therapy",
                "CIML NK cell therapy",
                "cytokine induced memory-like natural killer cell therapy",
                "immunotherapy",
                "antibody-dependent cell-mediated cytotoxicity",
                "ADCC",
                "CD38 positive",
                "CD38+",
                "plasma cells",
                "multiple myeloma",
                "hematological malignancies"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Newly diagnosed multiple myeloma patients",
                    "type": "EXPERIMENTAL",
                    "description": "Newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT)",
                    "interventionNames": [
                        "Combination Product: CIML NK Cells plus KP1237 and low dose IL-2"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "CIML NK Cells plus KP1237 and low dose IL-2",
                    "description": "Single dose infusion of CIML NK Cells plus KP1237 followed by low dose IL-2",
                    "armGroupLabels": [
                        "Newly diagnosed multiple myeloma patients"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose limiting toxicities following Combination Product dministration",
                    "timeFrame": "100 days post Combination Product administration"
                },
                {
                    "measure": "Incidence and severity of side effects related to the Combination Product",
                    "timeFrame": "100 days post Combination Product administration"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Rate of MRD conversion from positive to negative",
                    "timeFrame": "90-100 days post-ASCT"
                },
                {
                    "measure": "Rate of MRD conversion from positive to negative",
                    "timeFrame": "1 year post-ASCT"
                },
                {
                    "measure": "Rate of MRD conversion from positive to negative during the maintenance phase",
                    "timeFrame": "Start of maintenance therapy 90-100 days post ASCT until disease progression (approximately 2-3 years)"
                },
                {
                    "measure": "Rate of PFS",
                    "timeFrame": "1 year post Combination Product administration"
                },
                {
                    "measure": "Rate of OS",
                    "timeFrame": "1 years post Combination Product administration"
                },
                {
                    "measure": "Best overall response rate per the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma",
                    "timeFrame": "90-100 days post-ASCT, 1 year post-ASCT, and overall during maintenance phase (approximately 3 years)"
                },
                {
                    "measure": "Incidence and severity of cytokine release syndrome per ASBMT consensus grading",
                    "timeFrame": "100 days post Combination Product administration"
                },
                {
                    "measure": "Incidence and severity of other Immune-related toxicities by CTCAE version 5.0",
                    "timeFrame": "100 days post Combination Product administration"
                },
                {
                    "measure": "PK of the KP1237 by determining plasma Cmax",
                    "timeFrame": "4 days post Combination Product administration"
                },
                {
                    "measure": "PK of the KP1237 by determining plasma Cmin",
                    "timeFrame": "4 days post Combination Product administration"
                },
                {
                    "measure": "PK of the KP1237 by determining plasma AUC",
                    "timeFrame": "4 days post Combination Product administration"
                },
                {
                    "measure": "PK of the KP1237 by determining plasma t1/2",
                    "timeFrame": "4 days post Combination Product administration"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Had measurable disease according to Standard Diagnostic Criteria at the time of initial Multiple Myeloma diagnosis\n* Meets criteria for symptomatic multiple myeloma at the time of induction chemotherapy\n* Is transplant eligible based on clinician judgement\n* Willing to undergo ASCT in first remission\n* Achieve partial response or better with induction chemotherapy prior to ASCT according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma\n* Be MRD+ disease upon restaging prior to stem cell collection and ASCT\n* Eastern Cooperative Oncology Group (EGOG) performance status score of less than 2\n* Life expectancy greater than six months\n* Have no evidence of active or decompensated heart failure, no recent history (past 6 months) acute myocardial infarction, no evidence of severe valvular disease and must have a LVEF over 50% at the time of transplant evaluation\n* Adequate kidney function\n* No evidence of moderate/severe restrictive or obstructive lung disease at the time of transplant evaluation\n* Adequate bone marrow function\n* Be willing to undergo CD34+ cell collection for stem cell transplant\n* Be willing to undergo leukapherisis\n* Adequate hepatic function\n* If of child-bearing potential, be willing to follow birth control and pregnancy testing practice as recommended\n* Be willing to undergo bone marrow aspirate and biopsy as per treatment plan\n\nExclusion Criteria:\n\n* Prior autologous or allogeneic hematopoietic stem cell transplant\n* Prior cellular therapies, including NK cell therapy\n* Prior treatment with monoclonal antibodies\n* Prior treatment with melphalan\n* Prior treatment with immunosuppressive or immunomodulatory agents within 30 days of enrollment\n* Disease progression at the time of enrollment\n* History of plasma cell leukemia at any time prior to enrollment\n* Patients seropositive for the human immunodeficiency virus (HIV)\n* Uncontrolled, Hepatitis C Virus or Hepatitis B Virus infection\n* Patient receiving other investigational or anti-myeloma drugs within 30 days of enrollment\n* Patients with active clinically significant autoimmune diseases\n* Patients with active, clinically significant cancer other than multiple myeloma\n* Patients with neurological conditions that make difficult the assessment of neurologic toxicity of the Combination Product",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Chief Medical Officer",
                    "role": "CONTACT",
                    "phone": "203-404-0410",
                    "email": "clinicaltrials@biohavenpharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Giada Bianchi, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20497",
                    "name": "Neoplasm, Residual",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}